Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.46 |
| ▸ | PLG | P00747 | 1/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.46 |
| ▸ | MME | P08473 | 1/20 | 0.45 |
| ▸ | ECE1 | P42892 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 2/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 2/20 | 0.43 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.43 |
| ▸ | TYR | P14679 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21643143 | 1.00 | TPSAB1 (0.46) | TPSAB1PLGPRSS1MMEECE1 | |
| SCHEMBL20467691 | 1.00 | TPSAB1 (0.46) | TPSAB1PLGPRSS1MMEECE1 | |
| SCHEMBL20467674 | 0.83 | CTSS (0.43) | TPSAB1PLGPRSS1CTSKCTSL | |
| SCHEMBL20467720 | 0.83 | CTSS (0.43) | TPSAB1PLGPRSS1CTSKCTSL | |
| SCHEMBL20467672 | 0.79 | TPSAB1 (0.53) | TPSAB1PLGPRSS1MMEECE1 | |
| SCHEMBL241564 | 0.79 | CTSK (0.61) | MMEECE1MEN1LMNAKMT2A | |
| SCHEMBL856196 | 0.79 | CTSK (0.61) | MMEECE1MEN1LMNAKMT2A | |
| SCHEMBL241565 | 0.79 | CTSK (0.61) | MMEECE1MEN1LMNAKMT2A | |
| SCHEMBL21643145 | 0.79 | CTSL (0.52) | CTSLCTSBCTSS | |
| SCHEMBL16574772 | 0.79 | ALB (0.44) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340916-A1 | METHOD FOR SYNTHESIZING PEPTIDES IN CELL-FREE TRANSLATION SYSTEM | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2025-11-06 | — | — | US | disclosed |
| US-12391971-B2 | Method for synthesizing peptides in cell-free translation system | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-08-19 | — | — | US | disclosed |
| US-20200040372-A1 | METHOD FOR SYNTHESIZING PEPTIDES IN CELL-FREE TRANSLATION SYSTEM | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2020-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200040372-A1 | METHOD FOR SYNTHESIZING PEPTIDES IN CELL-FREE TRANSLATION SYSTEM | AARS1, NSUN3, RNGTT | TPSAB1 2792/4885PLG 2747/4885PRSS1 596/4885 |
| US-12391971-B2 | Method for synthesizing peptides in cell-free translation system | AARS1, NSUN3, RNGTT | TPSAB1 2792/4885PLG 2747/4885PRSS1 596/4885 |
| US-20250340916-A1 | METHOD FOR SYNTHESIZING PEPTIDES IN CELL-FREE TRANSLATION SYSTEM | AARS1, NSUN3, RNGTT | TPSAB1 2792/4885PLG 2747/4885PRSS1 596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.